New PET scan for pancreatic cancer staging
Part of Cancer clinical trials.
This study tests a new type of PET scan that uses a radioactive tracer called FAPI-74 to find cancer spread in people with pancreatic cancer. The goal is to see if this scan can help doctors better plan treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with pancreatic ductal adenocarcinoma (PDAC) and are being evaluated to plan treatment.
- You are able to have a CT scan of your chest, abdomen, and pelvis within 3 weeks before or after the study PET scan.
- If you could become pregnant, you agree to use highly effective birth control during the study.
- You do not have cancer spread that makes surgery impossible, have not had prior treatment for PDAC, and do not have serious liver, kidney, or bowel disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan that uses a special tracer (FAPI) to get clearer images of pancreatic cancer. The goal is to find cancer earlier and better plan surgery or treatment.
This Phase 1 trial tests a new imaging agent (a radioactive tracer) that helps doctors see pancreatic cancer that has spread or cannot be removed by surgery. The scan uses positron emission tomography (PET), a type of imaging that detects cancer cells.
This trial tests a new PET scan drug (18F-FAPI) to see if it can better detect where stomach or esophageal cancer has spread. It may help doctors plan the right treatment for you.
This trial uses a special PET scan (68Ga-FAPI-46) to help see pancreatic cancer more clearly before surgery. The goal is to see if this new scan can find cancer that standard scans might miss, helping surgeons plan the best operation.
This trial tests a special PET/CT scan using a new tracer (68Ga-FAPI) to help show tumors in the pancreas, bile ducts, stomach, or certain ovarian cancers. It may help doctors better see where cancer is in preparation for surgery or biopsy.
This study uses a special PET scan drug (Ga-FAPI-46) to create clearer pictures of pancreatic and bile duct cancers. It may help doctors decide on the best next steps—especially before surgery—by checking tumor size and looking for spread.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.